GOLDEN, Colo. — Oct. 25, 2016 — PharmaJet today announced a collaboration with Vaccibody AS to provide needle-free injection technology for the study of a vaccine to eradicate HPV. This disease is the main cause of cervical cancer affecting 530,000 women globally annually, and an additional 10 million women are impacted by a long pre-invasive disease called Cervical Intraepithelial Neoplasis (CIN).1
“The phase 1 clinical data showed that not only does the vaccine appear to have an excellent safety profile, but the T-cell immune responses observed show that our vaccine (VB10.16) induces the strongest HPV16-specific immune response we have seen reported in the literature. While other DNA vaccines developed for this indication require delivery with in vivo electroporation, which is quite painful for the patients, VB10.16 is delivered by needle-free injection, which we believe improves patient compliance tremendously and will be a significant asset in further development of this product,” said Martin Bonde, CEO of Vaccibody AS.
“We are pleased that the PharmaJet device is being used for this important study, and are encouraged by the improved compliance that needle-free may provide. This is consistent with our survey data that shows 93% of patients would choose needle-free again for their next vaccination2,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc. “Given that multiple vaccine doses are required for the HPV vaccine, improved compliance with needle-free is an important advantage.”
To view Vaccibody’s announcement click here. For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Vaccibody announces positive results from the phase 1 part of the clinical trial, press release, Aug. 25, 2016. www.vaccibody.com/news
2 PharmaJet, Inc. (2014) 61-10201 Post Market Surveillance – internal company report, February, 2015.